American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · Apr 2010
ReviewBenefits and risks associated with beta-blocker prophylaxis in noncardiac surgery.
The benefits and risks associated with use of beta-blocker prophylaxis in noncardiac surgery (NCS) are described. ⋯ Perioperative use of beta-blockers in NCS can protect against postoperative MI but increases the risk of stroke, severe hypotension, and severe bradycardia. Although less common, the strokes are severe, and the troubling trend toward increasing cardiovascular and total mortality precludes the recommendation for their use in patients not previously treated with beta-blockers.
-
Am J Health Syst Pharm · Mar 2010
ReviewPharmacotherapeutic disparities: racial, ethnic, and sex variations in medication treatment.
Variations in the medication treatment received by racial and ethnic minorities and women and the negative health outcomes associated with these differences were examined. ⋯ A literature review revealed significant disparities in the medication treatment received by racial and ethnic minorities and women.
-
Am J Health Syst Pharm · Mar 2010
Strategies for implementing emergency department pharmacy services: results from the 2007 ASHP Patient Care Impact Program.
Strategies proposed during a patient care impact program for implementing emergency department (ED) pharmacy services are described. ⋯ Despite the diversity in practice settings, participants of the program faced similar challenges in implementing ED pharmacy services at their institutions. Various strategies toward solutions to these challenges were shared among participants and mentors.
-
Am J Health Syst Pharm · Mar 2010
Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage.
The use of coagulation factor VIIa (recombinant) for the treatment of warfarin-induced intracranial hemorrhage (ICH) is described. ⋯ Use of factor VIIa (recombinant) may be considered for reversal of anticoagulation in patients with warfarin-associated ICH. However, patients should be screened for increased risk of thrombosis before administration of the drug.
-
Am J Health Syst Pharm · Mar 2010
Clinical TrialWeight-based heparin protocol using antifactor Xa monitoring.
The performance of a weight-based dosing protocol for unfractionated heparin (UFH) infusions using antifactor Xa monitoring was evaluated. ⋯ A weight-based UFH dosing nomogram using antifactor Xa monitoring resulted in a high percentage of patients achieving target antifactor Xa values within the first 24 hours of therapy.